Haematologica
Journal
Overview
publication venue for
-
Morphologic and immunophenotypic characterization of lymphocytosis following BCMAtargeted CAR-T cell therapy in relapsed/refractory multiple myeloma.
2026
-
Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s).
2025
-
Wild-type p53 overexpression in NPM1-mutated acute myeloid leukemia: potential implications for disease biology and therapy response..
111.
2025
-
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy..
110.
2025
-
Lysine succinylation precisely controls normal erythropoiesis..
110.
2025
-
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience..
110.
2025
-
Increased frequency of clonal hematopoiesis of indeterminate potential in Bloom syndrome probands and carriers..
110.
2025
-
Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma..
109.
2024
-
Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies..
109.
2024
-
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy..
109.
2024
-
STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia..
109.
2024
-
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application..
109.
2024
-
Long non-coding RNA mitophagy and ALK-negative anaplastic lymphoma-associated transcript: a novel regulator of mitophagy in T-cell lymphoma..
108.
2023
-
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients..
108.
2023
-
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial..
108.
2023
-
Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity..
108.
2023
-
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy..
108.
2023
-
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis..
108.
2023
-
Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation..
108.
2023
-
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia..
108.
2023
-
Discordant SARS-CoV-2 spike protein receptor binding domain IgG and neutralization after B-cell depletion..
107.
2022
-
Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment..
107.
2022
-
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients..
107.
2022
-
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma..
107.
2022
-
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies..
107.
2022
-
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial..
106.
2021
-
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia..
106.
2021
-
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia..
106.
2021
-
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study..
106.
2021
-
Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target..
106.
2021
-
Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma..
106.
2021
-
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma..
106.
2021
-
Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells..
106.
2021
-
Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort..
105.
2020
-
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?.
105.
2020
-
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research..
105.
2019
-
Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders..
105.
2019
-
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription..
105.
2019
-
Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia..
104.
2019
-
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy..
104.
2019
-
Deubiquitylase USP7 regulates human terminal erythroid differentiation by stabilizing GATA1..
104.
2019
-
Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia..
104.
2019
-
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma..
104.
2018
-
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia..
104.
2018
-
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States..
103.
2018
-
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease..
103.
2018
-
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia..
103.
2018
-
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project..
103.
2018
-
Single-agent dabrafenib for BRAFV600E-mutated histiocytosis..
103.
2018
-
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results..
103.
2018
-
Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor..
102.
2017
-
The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope..
102.
2017
-
Bleeding risk of surgery and its prevention in patients with inherited platelet disorders..
102.
2017
-
Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT..
102.
2017
-
The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia..
102.
2017
-
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia..
101.
2016
-
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes..
101.
2016
-
Donor and recipient sex in allogeneic stem cell transplantation: what really matters..
101.
2016
-
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival..
101.
2016
-
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia..
100.
2014
-
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients..
99.
2014
-
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia..
99.
2014
-
Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics..
99.
2014
-
Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration..
99.
2014
-
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale..
99.
2014
-
Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up..
99.
2014
-
Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura..
99.
2013
-
Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors..
99.
2013
-
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma..
99.
2013
-
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies..
98.
2013
-
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features..
98.
2013
-
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis..
98.
2013
-
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells..
98.
2013
-
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia..
98.
2013
-
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia..
98.
2013
-
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia..
98.
2013
-
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia..
98.
2012
-
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study..
98.
2012
-
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine..
98.
2012
-
Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy..
97.
2012
-
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype..
97.
2011
-
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera..
97.
2011
-
Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial..
96.
2011
-
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens..
96.
2011
-
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type..
95.
2010
-
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma..
95.
2010
-
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies..
94.
2009
-
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells..
93.
2008
-
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia..
93.
2008
-
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial..
93.
2008
-
Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin delta..
93.
2008
-
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience..
93.
2008
-
The pattern of genomic gains in salivary gland MALT lymphomas..
92.
2007
-
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells..
90.
2005
-
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses..
90.
2005
-
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study..
88.
2003
-
The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis..
85.
2000
-
Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis..
81.
1996
-
Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings..
109.
2024
-
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis..
109.
2024
-
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry..
109.
2024
-
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial..
108.
2023
-
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study..
106.
2021
-
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research..
106.
2021
-
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database..
106.
2021
-
Acute myeloid leukemia shapes the bone marrow stromal niche in vivo..
106.
2021
-
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia..
106.
2021
-
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma..
106.
2021
-
Severe delayed hemolytic transfusion reaction due to anti-Fy3 in a patient with sickle cell disease undergoing red cell exchange prior to hematopoietic progenitor cell collection for gene therapy..
106.
2021
-
Germline biallelic PIK3CG mutations in a multifaceted immunodeficiency with immune dysregulation..
105.
2020
-
Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial..
105.
2020
-
Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression..
105.
2019
-
Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms..
105.
2019
-
Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia..
105.
2019
-
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1..
105.
2019
-
Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma..
104.
2019
-
Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900..
104.
2018
-
Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study..
104.
2018
-
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results..
103.
2018
-
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia..
103.
2018
-
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms..
103.
2017
-
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia..
102.
2017
-
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia..
101.
2016
-
Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation..
101.
2016
-
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure..
101.
2016
-
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study..
101.
2015
-
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study..
100.
2015
-
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma..
99.
2014
-
DNMT3A and stem cell function: new insights into old pathways..
97.
2012
-
Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature..
97.
2011
-
ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition..
96.
2010
-
Chromosomal translocations involving BCL6 in MALT lymphoma..
93.
2008
-
Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation..
90.
2005
-
Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura..
90.
2005
-
Immune surveillance of leukemia?.
90.
2005
-
Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now..
90.
2005
-
T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome..
88.
2003
-
A technique for detecting leukocyte-derived free radical production..
75.
1990
-
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?.
108.
2023
-
Cytomegalovirus-specific T cells following haploidentical transplants: reshaping a repertoire by half..
108.
2023
-
Leukemia stem cell gene expression signatures contribute to acute myeloid leukemia risk stratification..
105.
2020
-
New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches..
104.
2019
-
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials..
99.
2014
-
Extending the reach of nilotinib in chronic myeloid leukemia..
99.
2014
-
T315I, more or less, predicts for major molecular response: the devil is in the details!.
98.
2013
-
Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective..
95.
2010
-
Pathophysiology of Waldenström's macroglobulinemia..
95.
2010
-
Chronic myeloid leukemia in 2006: a perspective..
91.
2006
-
Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.
2025
-
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
2019
-
Thrombopoietin receptor agonists: ten years later.
2019
-
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
2016
-
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia.
2016
-
Epigenetic regulators and their impact on therapy in acute myeloid leukemia.
2016
-
A new prognostic score for AIDS-related lymphomas in the rituximab-era.
2014
-
Primary thrombocytosis in children.
2014
-
Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia.
2000
-
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia.
1997
-
Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
1990
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)